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Summary. Background: Currently there is no approved anti-
coagulant for treating acute stroke. This is largely because of
concern for hemorrhagic complications, and suggests a critical
need for safer anticoagulants. Solulin is a soluble analog of the
endothelial cell receptor thrombomodulin, able to bind free
thrombin and convert it to an activator of the anticoagulant,
protein C. Objective: Solulin was tested for its ability to inhibit
middle cerebral artery occlusion (MCAO) induced by photo-
thrombosis, and to restoreMCApatency after establishment of
stable occlusion. Methods: Cerebral blood flow (CBF) was
monitored by laser Doppler for 1.5 h after occlusion and again
72 h later.Results: Solulin treatment 30 min before thrombosis
resulted in an approximately 50% increase in time to form a
stable occlusion. When administered 30 or 60 min after
MCAO, Solulin significantly improved CBF within 90 min of
treatment. In contrast, none of the vehicle-treated mice showed
restoration of CBF in the first 90 min and only 17% did so by
72 h. Solulin treatment was associated with a significant
reduction in infarct volume, and was well tolerated with no
overt hemorrhage observed in any treatment group. Mecha-
nistic studies in mice homozygous for the factor (F)V Leiden
mutation, suggest that Solulins efficacy derives primarily from
the anticoagulant activity of the thrombin–Solulin complex and
not from direct anti-inflammatory or neuroprotective effects of
Solulin or activated protein C. Conclusions: Our data indicate
that Solulin is a safe and effective anticoagulant that is able to
antagonize active thrombosis in acute ischemic stroke, and to
reduce infarct volume.
Keywords: anticoagulants, cerebral-ischemia, hemorrhage,
stroke, thrombosis.
Introduction
Stroke is the leading cause of morbidity and the third leading
cause of mortality in the United States [1]. Approximately 80%
of acute strokes are ischemic with the rest being hemorrhagic.
Outcomes for hemorrhagic strokes are generally worse than for
ischemic strokes and hemorrhagic conversion of an ischemic
stroke markedly increases stroke severity [2]. Thus, although
the nature of ischemic stroke suggests the need for anticoag-
ulant intervention, there are currently no approved anticoag-
ulants for treating acute stroke. Similarly, low-dose aspirin is
the only anti-platelet drug currently recommended, and only
within the first 24–48 h in patients with mild stroke [3], and all
anticoagulant/platelet therapy is contraindicated within 24 h of
thrombolysis with tissue type plasminogen activator (tPA) [4].
Many clinical studies have investigated anticoagulants in
ischemic stroke, with the rationale that treatment would
prevent ongoing thrombosis, maintain collateral circulation,
halt recurrent stroke and reduce neurological deficits. In spite
of these studies, the effectiveness of anticoagulants is still
controversial, with a recent study suggesting that early
anticoagulation can provide benefit, but at the risk of increased
symptomatic brain hemorrhages [5]. Likewise, a meta-analysis
of data from eight separate clinical trials, involving more than
22 000 participants, found that while early anticoagulation did
reduce the incidence of recurrent ischemic stroke, this benefit
was offset by an increase in symptomatic intracranial hemor-
rhages, and that overall there was no evidence that anticoag-
ulation reducedmortality or dependence [6]. Thus, these studies
suggest that a safer anticoagulant therapy could provide
significant benefit in ischemic stroke patients.
An important innate system for controlling thrombosis is
activation of the serine protease Protein C, to activated protein
C (APC), a potent anticoagulant that inactivates coagulation
cofactors Va and VIIIa [7,8]. APC is generated by thrombin;
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however, this process is extremely inefficient in the absence of
the cofactor, thrombomodulin. Thrombomodulin is a receptor
present on the luminal surface of intact endothelium that binds
thrombin with high affinity (Kd = 0.5–1 nM) and increases its
activation of protein C by more than 20 000-fold, switching
thrombin from a procoagulant to an anticoagulant enzyme
[7,9]. Thrombomodulin-bound thrombin can also activate the
thrombin-activatable fibrinolysis inhibitor (TAFI) [10,11].
Thus, thrombomodulin naturally limits thrombosis at sites
where the endothelium is intact, and through TAFI it can also
moderate thrombolysis. The dependency on active free throm-
bin makes thrombomodulin an attractive candidate as an
anticoagulant as it will exert anticoagulant activity only after
the initiation phase of thrombin generation and hence will not
impact formation of the primary hemostatic plug.
Solulin is a recombinant soluble analog of human thrombo-
modulin. It is a single-chain glycoprotein consisting of the
extracellular domains of thrombomodulin modified by a few
specific mutations and deletions that distinguish Solulin from
similar products such as thrombomodulin alfa (ART-123)
(Data S1). Otherwise, Solulin shares with thrombomodulin its
essential mechanisms of action, including binding active throm-
bin and activation of proteinC andTAFI [11]. The requirement
for active thrombin restricts Solulins activity to sites with
increasedsoluble thrombin,whichmay improve its safetyprofile
and reduce the risk of hemorrhagic complications in stroke
patients. The anticoagulant properties of Solulin have been
verifiedinpreviousstudiesinrodentmodels[12](datanotshown)
and are similar to those reported for thrombomodulin alfa [13].
In the present study, Solulin was tested for its ability to
prevent thrombosis in themiddle cerebral artery (MCA), restore
MCApatency afterMCAO, improve outcomes asmeasured by
stroke lesion volume, and todo sowithout causing intracerebral
hemorrhage. Finally, the mechanism of Solulins action was
assessed by examining its efficacy in mice homozygous for the
factor (F)V Leiden mutation, which makes its carriers resistant
to the anticoagulant activity of APC [8,14].
Methods
Ischemic stroke model
Male C57Bl/6J and FV Leiden mice [14] (10 weeks) were
anesthetized with chloral hydrate (450 mg kg)1) and placed
securely under a dissecting microscope. The left MCA was
exposed as described [15], and a laserDoppler flowprobe (Type
N: Transonic Systems, Ithaca, NY, USA) was placed on the
surface of the cerebral cortex located 1.5 mm dorsal median
from the bifurcation of MCA. The probe was connected to a
flowmeter (Transonic model BLF21) and relative tissue perfu-
sion units (TPU) was recorded with a continuous data
acquisition program (WINDAQ,DATAQ,Akron,OH,USA).Rose
Bengal (RB) (Fisher) was diluted to 10 mg mL)1 in Lactate
Ringers and then injected into the tail vein (50 mg kg)1). A 3.5-
mWgreen light laser (540 nm;MellesGriot,Albuquerque,NM,
USA)wasdirected at theMCAfromadistanceof 6 cm, and the
TPU of the cerebral cortex was recorded. Stable occlusion was
achieved when the TPU dropped to < 20% of pre-occlusion
levels and did not rebound within 10 min after Laser with-
drawal. All animal experiments were approved by the Institu-
tional AnimalCare andUseCommittee ofUnit for Laboratory
Animal Medicine at University of Michigan, and followed the
STAIR recommendations for preclinical studies (Data S1).
Solulin delivery and cerebral blood flow tracing
Solulin was administered via a 26-G Abbocath-T vascular
catheter (Hospira, Lake Forest, IL, USA) inserted into the tail
vein and connected to a Genie Plus syringe pump (Kent
Scientific, Torrington, CT, USA). Mice received either 200 lL
of Lactate Ringers (controls) or 200 lL of Solulin (1, 3 or
10 mg kg)1) either 30 min before RB injection, or 30 or 60 min
after MCAO.
All cerebral blood flow (CBF) tracings were started 10 min
before RB injection and the average CBF over this time was
considered 100%andused tonormalizeCBF.Timezerowas set
at RB injection. Seventy-two hours afterMCAO, animals were
re-anesthetized with chloral hydrate (450 mg kg)1) and the
surgical site was re-exposed and theDoppler flow probe was re-
attached to the same locationasbefore toobtain72-hCBFdata.
Stroke volume
The assessment of stroke volume was performed essentially as
described [15]. Briefly, brains were removed and cut into 2-mm-
thick coronal sections and stained with 4% 2,3,5-triphenyltet-
razolium chloride (TTC) in phosphate-buffered saline (PBS)
for 20 min at 37 C, and then fixed in 4% paraformaldehyde
solution for 10 m. The sections were analyzed with NIH IMAGE J





(Areas of ipsilateral hemi-
sphere) · 100,
where V%stroke is stroke volume calculated as percent of the
ipsilateral hemisphere.
Hemoglobin assay
Twenty-four hours after MCAO, brains were removed,
separated into hemispheres ipsilateral and contralateral to the
MCAO, and each hemisphere was homogenized in 475 lL of
PBS on ice. Approximately 25 lL of 10% Triton X-100 was
added to a final concentration 0.5%. After mixing, samples
were incubated at 23 C for 5 min and then centrifuged at
25 000 g at 4 C for 30 m. The absorbance of 50 lL of the
supernatant was read at 410 nm and the hemoglobin quantified
relative to a purified hemoglobin standard (Sigma-Aldrich, St.
Louis, MO, USA) as described [15].
Immunohistochemistry
Paraffin-embedded sections (5 lm) from vehicle- and Solulin-
treated animals euthanized 72 h after MCAO were examined
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using the Apoptag kit (Oncor, Gaithersburg, MD, USA)
according to the manufacturers instructions. The slides were
developed with peroxidase substrate diaminobenzidinetetrahy-
drochloride for 5 min (Sigma-Aldrich), washed in Milli-Q
deionized H2O for 5 min and counterstained with 0.5%methyl
green for 10 min. To quantify cells with apoptotic bodies, an
area surrounding the ischemic core extending from the cerebral
cortex to the most anterior (septal) part of the hippocampus
was imaged in vehicle and Solulin-treated animals. Three
random fields were chosen and TUNEL positive cells were
quantified under a 40 · objective [17].
Statistical analysis
Data were analyzed using Student¢s t-test (Excel; Microsoft,
Redmond, WA, USA) and ANOVA with Bonferronis Post Test
(Prism; GRAPHPAD, La Jolla, CA, USA), P £ 0.05 was consid-
ered significant.
Results
Solulin extends time to occlusion in a photothrombotic model
We hypothesized that Solulin might be an effective and safe
alternative to existing anticoagulants in the setting of
thrombotic stroke. To determine Solulins capacity to prevent
thrombosis, we compared intravenous bolus injections of 1 or
3 mg kg)1 of Solulin in a photothrombotic model of MCAO.
Solulin was administered, and 30 min later thrombosis was
initiated by the injection of the photoactive dye, RB and its
local activation with a 540 nm laser. Laser Doppler flow
measurements were initiated 10 min before RB injection to
obtain baseline pre-occlusion CBF values and monitoring
was continued for at least 120 min. These data demonstrated
that Solulin treatment significantly increased the time to
stable occlusion of the MCA from an average of 7.5 min in
control animals to 13 or 12.5 min in the 1 or 3 mg kg)1
Solulin-treated animals, respectively (Fig. 1A,B). Further-
more, Solulin promoted reperfusion, as demonstrated by
increased CBF at later times in both groups of Solulin-
treated mice compared with controls (Fig. 1A). To quantify
the relative reperfusion, the area under the CBF curves
(AUC) was integrated and this analysis showed a significant
increase with both 1 and 3 mg kg)1 Solulin treatment
(Fig. 1C). Reperfusion was also analyzed by determining
the average CBF values 90 min after RB injection (Fig. 1D).
The dashed line indicates an arbitrary cutoff for animals
considered to show signs of reperfusion (CBF > 20% of pre-
occlusion levels). Only one out of 10 control mice was above
this cutoff, whereas five out of 10 animals showed improved
reperfusion both in the 1 and 3 mg kg)1 Solulin-treated
groups, and this pattern persisted 72 h later (not shown).
Moreover, both Solulin-treated groups showed statistically
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Fig. 1. Solulin inhibits ongoing thrombosis in the middle cerebral artery (MCA). Time zero was set at Rose Bengal (RB) injection. Cerebral blood flow
(CBF) tracings were started 10 min before RB injection and the average CBF from )10 to 0 was considered 100% and used to normalize all CBF
measurements. (A) Individual CBF tracing after treatment with either control or Solulin (1 or 3 mg kg)1) and (B) analysis of time needed for stable
occlusion after RB injection. Time to occlusionwasmeasured from time ofRB injection (30 min after injection of Solulin) to the time a stable occlusionwas
formed. (C) Analysis of relative vascular patency in MCA. Area under the curve (AUC) of each CBF tracing from RB injection to 120 min post injection
was integrated. (D) Analysis of reperfusion. CBF tracings from 85 to 90 min after RB injection were normalized against pre-occlusion CBF to show
individual data and averages (horizontal lines). The dashed line shows 20% of pre-occlusion CBF and acts as an arbitrary cutoff point for signs of
reperfusion. Each group has n = 10 except the 3 mg kg)1 group, which has n = 9 and errors represent standard error of the mean (SEM) *P < 0.05 vs.
control, and **P < 0.01.
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were analyzed regardless of the cutoff line (Fig. 1D). This
suggested that Solulin reduced the thrombotic response, and
in doing so may have tipped the balance towards endogenous
thrombolysis.
Solulin increases reperfusion after MCAO
To test whether Solulin was effective after a stable occlusion of
the MCA had already formed, Solulin, 1 mg kg)1, was
administered either 30 or 60 min after MCAO. Figure 2A
shows continuous Laser Doppler monitoring of CBF for up to
2.5 h after RB injection. Occlusion of the MCA began shortly
after RB injection and was stabilized between 5 and 10 min
after injection in all mice. In vehicle-injected mice the occlusion
remained stable for the duration of the monitoring in all mice.
In contrast, CBF tracings of mice treated with Solulin 30 or
60 min after MCAO showed that after Solulin delivery there
was a partial restoration of CBF, beginning approximately
20 min after the initiation of Solulin administration. The extent
of this reperfusion induced by Solulin treatment was calculated
by integrating the area under the CBF curves (AUC), and these
data demonstrated a statistically significant increase in CBF for
both Solulin-treatment groups (Fig. 2B,D). When CBF was
analyzed again 72 h after the initial occlusion, an average of
approximately 73% of the pre-occlusion CBF value was
observed in the 30-min Solulin-treated group (Fig. 2C). How-
ever, reperfusion at 72 h did not persist in the 60-min Solulin-
treated group (Fig. 2E). These data demonstrated that Solulin
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Fig. 2. Solulin partially restores middle cerebral artery (MCA) patency after establishment of stable occlusion. (A) Cerebral blood flow (CBF) for mice
treated with vehicle or 1 mg kg)1 of Solulin at either 30 or 60 min post occlusion. (B, D) Quantitative analysis of relative vascular patency in MCA from
the CBF tracings in panel A, with injection 30 min (B) or 60 min (D) after occlusion. The area under the curve (AUC) of the CBF tracings was integrated
for 90 min from the time of Solulin or vehicle injection. (C and E) Analysis of relative vascular patency inMCA 72 h post occlusion. CBF was determined
over a 5-min period and normalized to pre-occlusion CBF. Each group n = 10 and errors represent standard error of the mean (SEM) **P < 0.01.
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markedly increased vascular reperfusion in theMCAwithin the
first 2 h afterMCAO. This benefit in reperfusion was sustained
for up to 3 days if Solulin was initiated 30 min after MCAO
(Fig. 2C), but was transient when Solulin administration was
delayed until 60 min after MCAO (Fig. 2E).
Solulin reduces infarct volume in wild-type mice
As increasing early reperfusion during ischemic stroke may
impact infarct expansion and improve stroke outcome, we
tested whether Solulin treatment also mitigates brain damage.
For this analysis stroke lesion volumes were compared in wild-
type mice treated with Solulin (1 mg kg)1) or vehicle either 30
or 60 min afterMCAO.Animals treated with Solulin showed a
significant 48.8% or 30.6% reduction in stroke volume
compared with vehicle-treated mice when Solulin was admin-
istered 30 (Fig 3B) or 60 min (Fig. 3A–C) after MCAO,
respectively. These data suggested that Solulin produced
marked beneficial effects after stroke.
Solulin does not increase hemorrhagic transformation after
MCAO
As one of the primary reasons that anticoagulants are not used
in ischemic stroke is the potential risk of hemorrhagic







































Fig. 3. Solulin reduces infarct volume in wild-type mice. (A) Represen-
tative images of 2,3,5-triphenyltetrazolium chloride (TTC)-stained 2-mm-
thick coronal sections with 1 mg kg)1 Solulin treatment 60 m after middle
cerebral artery occlusion (MCAO). (B) Quantification of infarct size 72 h
after MCAO in wild-type mice treated with either Solulin or vehicle
30 min after MCAO (n = 6 for control and n = 10 for Solulin). (C)
Quantification of infarct size 72 h after MCAO in wild-type mice treated
with either Solulin or vehicle 60 min afterMCAO [n = 10 for control and




















































Fig. 4. Quantification of hemoglobin and TUNEL positive cells in brain
tissue after middle cerebral artery occlusion (MCAO). (A) Quantification
of cerebral hemoglobin 24 h after MCAO in wild-type mice treated with
either Solulin (1 or 10 mg kg)1), heparin (100-U kg)1) or vehicle [n = 10
per group and errors represent standard error of the mean (SEM)].
Treatments were given intravenously 60 min after MCAO. *P < 0.05 vs.
control. (B) Representative coronal sections, stained with hematoxylin and
eosin stain (H&E) (top panels, outlined areas indicate infarct region) and
TUNEL (middle panels) 72 h after MCAO. High-resolution images of
TUNEL staining from a field in the penumbra are shown in the bottom
panels. Scale bars in the top and middle are 1 mm, and 50 lM in the
bottom. (C) Quantification of TUNEL positive cells in the penumbra
region (rectangular boxes in B middle panels) 72 h after MCAO.
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increased hemorrhage during cerebral ischemia. Vehicle or
Solulin (1 or 10 mg kg)1) was administered 60 min post-
MCAO. Twenty-four hours after MCAO, brain tissues were
perfused with PBS and processed for hemoglobin measure-
ment. Figure 4A shows that there is no significant difference in
the average hemoglobin content in the brain tissue of the
vehicle-treated group compared with the Solulin-treated
groups, even when 10 times the efficacious dose of Solulin
was used (10 mg kg)1). Furthermore, neither macroscopic nor
microscopic examination of the infarct tissue showed overt
signs of hemorrhage in Solulin-treated mice (not shown). These
data suggest that Solulin does not increase the risk of
hemorrhagic complications when given after MCAO. In
contrast, heparin-treated animals showed significantly more
hemoglobin in the brain after stroke, compared with either
control- or Solulin-treated mice (Fig. 4A). This is consistent
with previous reports in mice that heparin treatment after
stroke can exacerbate intracerebral hemorrhage [16,18], and in
human stroke patients where heparin treatment is associated
with an increased incidence of hemorrhagic transformation [5].
The effect of Solulin treatment on cell death in the penumbra
after MCAO
Analysis of neuronal cell death in the penumbra of the infarct
was performed using immunohistochemical TUNEL staining.
Quantification of TUNEL-positive cells in the region shown in
the box in Fig. 4B demonstrated that there was no difference in
the extent of neuronal death in the penumbra between the
Solulin-treated and untreated groups (Fig. 4C). This suggests
that Solulin was not acting as a direct neuroprotectant but
reduced overall infarct size by acting as an anticoagulant and
improving CBF.
Solulins protective effect absent in FV Leiden mice
To further examine whether Solulins protective effect after
MCAO was because of its anticoagulant activity or mediated
by neuroprotective or anti-inflammatory effects described for
both thrombomodulin/Solulin and APC, Solulin was admin-
istered to FV Leiden mice [14] 60 min after stroke induction,
and stroke lesion volumes were evaluated 72 h after MCAO
(Fig. 5A). These data demonstrate that unlike wild-type
animals (Fig. 3A,B), FV Leiden mice treated with Solulin did
not show any reductions in infarct size. This implies that the
protection mediated by Solulin is directly related to its APC-
mediated anticoagulant activity, rather than other effects of
Solulin, or APC, as in FV Leiden mice Solulin should still bind
thrombin and stimulate APC generation to the same extent as
wild-type mice, but would differ in their specific resistance to
the anticoagulant activity of APC. Consistent with this
hypothesis, CBF tracings of FV Leiden mice confirmed that
Solulin treatment did not produce a significant increase in
reperfusion after MCAO (Fig. 5B,C). This suggests that
Solulins protective effect is dependent on its anticoagulant
activity, mediated by APCs ability to inactivate FV.
Discussion
Anticoagulants have been evaluated in several major clinical
trials for efficacy in acute ischemic stroke, including warfarin,
unfractionated heparin, low-molecular-weight heparin or he-
parinoids [5,6,19–21]. However, these studies have been
inconclusive, failing to establish unequivocal beneficial effects
on clinical outcome in either the short or long term. Instead, the
anticoagulants studied have been invariably linked to a
significant increase in intracranial bleeding, and so their use
in acute ischemic stroke is contraindicated. Likewise, platelet




















10 30 50 70 90
Time after Rose Bengal (min) 
Time after Rose Bengal (min) 
110 130 150







































Fig. 5. Solulin is not protective in factor (F)V Leiden mice. (A) Quanti-
fication of infarct size 72 h after middle cerebral artery occlusion (MCAO)
in FV Leiden mice treated with either Solulin (1 mg kg)1) or vehicle
[n = 8 for control and n = 9 for Solulin; errors represent standard error
of mean (SEM)]. Solulin was given via intravenously 60 min afterMCAO.
In panels B (vehicle) and C (Solulin), Time zero was set at Rose Bengal
(RB) injection. All cerebral blood flow (CBF) tracings were started 10 min
before RB injection and the average CBF over this time was used to
normalize other CBF measurements.
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intracranial hemorrhage and mortality, and failed to show
efficacy, suggesting that this class of drugs does not offer a safe
alternative [22]. Thus, stroke presents a unique set of challenges
for the therapeutic use of anticoagulants.
Solulin, a soluble analog of human thrombomodulin that
lacks the transmembrane and cytoplasmic domains of endo-
genous thrombomodulin, has been engineered to be resistant
to oxidation and proteolysis, and to have a prolonged half-life
in plasma (Data S1). Functionally, Solulin is equivalent to
thrombomodulin in its primary extracellular mechanisms of
action. Once thrombin generation occurs, Solulin binds to
active thrombin and the thrombin–Solulin complex efficiently
activates TAFI, and hence reduces thrombolytic activity
[10,11]. However, at higher Solulin concentrations, activation
of protein C predominates [23,24]. APC inactivates coagulation
cofactors Va and VIIIa, curbing the thrombin burst that
normally occurs in the propagation phase of coagulation,
making Solulin an efficient anticoagulant [7,8]. APC also
down-regulates TAFI activation and enhances thrombolytic
activity [23,24]. Thus, thrombins ability to initiate clot
formation prevails, while clot extension and maturation are
inhibited. This mechanism is unlike those of existing anticoag-
ulants which inactivate thrombin directly, and consequently
Solulin may have a lower impact on hemostasis than seen with
other anticoagulants.
The present study supports the hypothesis that Solulin
treatment reduces stroke lesion volume through local activa-
tion of protein C, which shifts the coagulation/thrombolytic
balance towards a reduced thrombus burden and increased
cerebral perfusion. Pharmacokinetic data strongly suggest that
the Solulin doses we employed should have markedly sup-
pressed thrombin generation (Data S1). Intravenous injection
of Solulin before the onset of thrombosis increased the time
needed to form a stable occlusion in the MCA, and increased
overall CBF, clearly demonstrating that Solulin is an effective
anticoagulant. Solulin administration 30 min after stable
MCAO also enhanced reperfusion, and reduced infarct volume
by nearly 50%. This indicates that even after a stable thrombus
has formed Solulin can still promote recanalization and
improve outcome. In mice treated 60 min after MCAO, CBF
in the territory immediately proximal to the MCAO was
significantly improved only during the first 2-h observation
period; however, infarct volume was still reduced by 30%. This
suggests that while late treatment with Solulin may not be as
effective as early delivery, it may still alter the coagulation/
thrombolytic balance at sites distal to the MCAO, which may
not be apparent in CBF measurements proximal to the
MCAO, but may still improve reperfusion in the periphery of
the ischemic zone enough to reduce infarct expansion.
To confirm the hypothesis that Solulins protective benefit
after MCAO was mediated primarily by the generation of
APC, we used a mutant mouse strain carrying the murine
equivalent of the FV Leiden mutation, which makes FVa
resistant to APC cleavage and inactivation. We hypothesized
that if Solulins benefit in ischemic stroke was as a result of
generation of APC, then FV Leiden mice should show no
benefit from Solulin treatment. The present results supported
this conjecture and demonstrated that the FVLeidenmice were
not protected with regard to either stroke lesion volume or
decreases in CBF compared with control animals. As these
mice are directly resistant to the anticoagulant activity of APC
then this suggests that the primary benefit of Solulin arises from
its ability to promote APC-mediated anticoagulation through
the inactivation of FVa. However, it is also possible that
unrestrained thrombin generation in these mice could support
direct activation of TAFI by thrombin, resulting in a hypoth-
rombolyic state, as has been described with FV Leiden in both
humans and mice [25,26]. Thus, it is not possible to definitively
determine to what extent improvements in reperfusion and
reductions in infarct volumes in wild-type mice were due
directly toAPC-mediated anticoagulant activity or indirectly to
enhancement of endogenous thrombolytic activity. Nonethe-
less, both activities would be expected to reduce thrombus
extension and stabilization, and to tip the balance from
coagulation towards thrombolysis.
It is also possible that Solulin binding to thrombin could
have direct anti-thrombin activity, preventing interaction with
fibrinogen or other procoagulant substrates, or could provide
direct neuroprotectection through its ability to reduce throm-
bin diffusion through a compromised blood–brain barrier, and
the attendant thrombin neurotoxicity [27]. With regard to
direct anti-thrombin activity, previous studies of thrombin-
induced mortality in mice have shown that Solulin does not act
by inhibiting active thrombin injected into mice, but instead
acts by reducing the generation of additional thrombin [12].
With regard to direct neuroprotection, this too seems unlikely
for two reasons: first, in the FVLeidenmice, Solulin should still
bind thrombin and reduce its diffusion into the central nervous
system (CNS), and yet the relative stroke volumes in Soluin-
treated FV Leiden mice were indistinguishable from vehicle-
treated FV Leiden mice. Second, thrombin neurotoxicity is
generally associated with an increased loss of blood–brain
barrier integrity and intracerebal hemorrhage [28,29], and no
increase in overt intracerebal hemorrhage was noted in the FV
Leiden mice.
APC has also been reported to be directly neuroprotective
when infused immediately before or after MCAO, and this
activity is independent of its anticoagulant activity [30,31].
However, our data do not support this mechanism for Solulin,
as the FV Leiden mutation completely suspends Solulins
efficacy even although Solulin should still promote generation
of APC in these mice. The reason for this difference may be
because of systemic effects associated with the direct admin-
istration of APC, or the timing of treatment relative to ischemia
in the two cited studies, or more likely to differences in the local
or systemic concentrations of APC.
In contrast to mice treated with heparin [18] (Fig. 4A),
Solulin-treated animals showed no significant increases in brain
hemorrhage after MCAO. This suggests that Solulin may have
a better safety profile than existing anticoagulants. We
speculate that this is as a result of the generation of
anticoagulant activity only at sites where free active thrombin
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has reached a sufficient concentration. As a result, and unlike
other anticogulants such as heparin [32], Solulin will not inhibit
the initiation phase of coagulation, but only clot extension and
maturation, and in the absence of active soluble thrombin,
Solulin will be virtually inert. This unique characteristic of
Solulin sets it apart from other anticoagulants and may
increase its therapeutic potential.
It is also important to note that although Solulins primary
mode of action appears to be through the activation of protein
C, it does not appear to produce the same bleeding risk that the
direct administration of APC does [33] (Data S1). The reduced
susceptibility to bleeding associated with Solulin compared
with APC is most likely because of markedly different
concentration profiles of APC in the circulation during direct
APC infusion compared with Solulin administration, as with
Solulin, APC is generated only locally and incidental to
thrombin generation. Finally, the safe use of Solulin in humans
has been demonstrated in a recent phase I study, in which
Solulin at single doses up to 30 mg, and multiple doses up to
10 mg, was able to reduce endogenous thrombin potential by a
maximum of 98% without any signs of enhanced bleeding
tendency [34].
In summary, our data provide in vivo evidence that Solulin
facilitates recanalization and reduces stroke volume after
MCAO, and supports the suggestion that Solulin may have
utility as a novel anticoagulant, able to curb thrombin
generation with a promising safety profile in cerebral ischemia.
The efficacy of Solulin seems to be mediated through the local
formation of APC, which inhibits further intravascular
thrombin formation by inactivating coagulation cofactors Va
and VIIIa and thus antagonizes occluding clot growth.
Another significant consequence of thrombin down-regulation
may lie in a suppression of TAFI activation, promoting
effective clot lysis by endogenous tPA. These features enable
robust but local antithrombotic activity without causing global
impairment of hemostatic pathways. Future studies are needed
to further explore the potential of Solulin for the treatment of
ischemic stroke. These include its potential to prevent re-
occlusion after thrombolysis or mechanical thrombectomy,
and treatment at later times after MCAO as in the clinic it will
be necessary to differentiate between hemorrhagic and ischemic
stroke before Solulin can be administered.
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